NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), announced today that its latest joint venture target, Amarantus BioSciences, Inc. (OTCBB: AMBS), expects to announce the results of a preclinical study evaluating the potential of its new protein therapy as a treatment for Traumatic Brain Injury (TBI).
